Christoph Schwering

Best practices for the use of intracerebroventricular drug delivery devices

Irene Slavc, Jessica Cohen‐Pfeffer, Sridharan Gururangan et al. · Molecular Genetics and Metabolism · 2018 · 73 citations · Full text

Icv Drug Delivery, Pharmacotherapy, Biomedical Engineering +17

Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study

Angela Schulz, Nicola Specchio, Emily de los Reyes et al. · The Lancet Neurology · 2023 · 40 citations

Open-label Extension Study, Medicine, Cerliponase Alfa +4

Development of the “Hamburg Best Practice Guidelines for ICV−Enzyme Replacement therapy (ERT) in CLN2 Disease” Based on 6 Years Treatment Experience in 48 Patients

Christoph Schwering, Gertrud Kammler, Eva Wibbeler et al. · Journal of Child Neurology · 2021 · 19 citations · Full text

Neurological Disorder, Immunodeficiencies, Cln2 Disease ” +16

Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)

Simon Dulz, Christoph Schwering, Jan Wildner et al. · British Journal of Ophthalmology · 2022 · 19 citations

Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series

Eva Wibbeler, Raymond Wang, Emily de los Reyes et al. · Journal of Child Neurology · 2020 · 16 citations · Full text